Metrics details. Vasculopathy of the large vessels commonly occurs in sickle cell disease, and as a result cerebral infarction is a well characterized complication of this condition. However, spinal infarction appears to be rare. Spinal infarct is infrequent in the non-sickle cell population as well, and accounts for only about 1 percent of all central nervous system infarcts. In the present work, we report the case of a year-old African-American man with sickle cell disease who experienced an anterior spinal infarct and subsequent quadriplegia. He was incidentally noted to be a heterozygote for factor V Leiden.
Glossary | Linus Pauling Institute | Oregon State University
Sickle cell disease SCD is an inherited blood cell disorder estimated to affect , people in the United States. The blockage can cause pain and other serious problems such as infection, acute chest syndrome, and stroke. SCD affects nearly every organ system in the body and causes a lower life expectancy. Below are the main findings:. Our understanding of COVID among people with SCD continues to evolve, and additional investigations are needed to confirm the findings reported in this study. People with SCT are those who inherit one sickle cell gene and one normal gene.
Recent Advances in the Treatment of Sickle Cell Disease
Gene therapy is an experimental technique that aims to treat genetic diseases by altering a disease-causing gene or introducing a healthy copy of a mutated gene to the body. The U. Sickle cell anemia is caused by a mutation in the HBB gene which provides the instructions to make part of hemoglobin, the protein in red blood cells that carries oxygen. Researchers are working on two different strategies to treat sickle cell anemia with gene therapy. These are cells in the bone marrow that divide and specialize to produce different types of blood cells, including the red blood cells.
Metrics details. Sickle cell disease SCD is an inherited blood disorder that results in a lifetime of anemia, severe pain, and end-organ damage that can lead to premature mortality. While the SCD field has made major medical advances, much needs to be done to improve the quality of care for people with SCD. This report documents the process to support the consortium by specifying the interventions being developed.